RBC Capital analyst Craig Wong-Pan raised the firm’s price target on ResMed (RMD) to $314 from $311 and keeps an Outperform rating on the shares. The company delivered a strong result with double-digit revenue and earnings growth, the analyst tells investors in a research note. ResMed achieved robust growth across all markets and continued to deliver gross margin improvement and operating leverage, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: